1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2024 | |
|---|---|---|
| Revenue | 553.97K | 73.21% |
| Gross profit | 126.63K | 85.70% |
| Net profit | -10.9M | 14.25% |
| EBITDA | -9.81M | 20.16% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €4.88M |
Number of shares | 69.64M |
52-week high/low | €0.35 - €0.00257 |
| Dividends | No |
Beta | 1.08 |
P/E ratio | -0.23 |
PEG ratio | 0.00 |
P/B ratio | -0.29 |
P/S ratio | 8.61 |
Company profile
| Name | Argent BioPharma Aktie |
| CEO | Roby Reuven Zomer |
Ticker symbols
| Exchange | Symbol |
|---|---|
Frankfurt | H5O0.F |
London | RGT.L |
Düsseldorf | H5O0.DU |
Discover assets
Shareholders of Argent BioPharma Aktie also invest in the following assets
